Epstein-Barr virus-associated lymphoproliferative disorder
MONDO:0017343A range of lymphoproliferative diseases characterized by uncontrolled proliferation of B cells, T cells, or NK cells infected with Epstein-Barr virus. Depending on host immunity and viral factors, viral persistence in host cells can induce lymphoproliferation with a diverse clinical spectrum ranging from simple reactive hyperplasia to aggressive lymphoma/leukemia with unique clinical and pathological presentations.
Also known as: EBV-associated lymphoproliferative disorder, Epstein-Barr virus-associated malignant lymphoproliferative disorder
2134 clinical trials for this condition and its sub-types, 22 tagged with Epstein-Barr virus-associated lymphoproliferative disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Epstein-Barr virus-associated lymphoproliferative disorder
-
Hodgkins lymphoma 262 trials · 326 incl. sub-types
5 sub-types
- Classic Hodgkin lymphoma 147 trials · 149 incl. sub-types Sub-types →
- Nodular lymphocyte predominant Hodgkin lymphoma 5 trials · 6 incl. sub-types Sub-types →
- Lymphoma, Hodgkin, X-linked pseudoautosomal 0 trials
- Lymphoma, Hodgkin, Y-linked pseudoautosomal 0 trials
- Splenic hodgkin lymphoma 0 trials
-
Burkitt lymphoma 220 trials
2 sub-types
- Colon Burkitt lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
-
Primary central nervous system lymphoma 92 trials · 103 incl. sub-types
3 sub-types
- Central nervous system non-hodgkin lymphoma 1 trial · 22 incl. sub-types Sub-types →
- Cerebral lymphoma 2 trials
- Spinal cord lymphoma 0 trials
-
Extranodal nasal NK/T cell lymphoma 51 trials
-
Plasmablastic lymphoma 20 trials
-
Primary effusion lymphoma 18 trials
-
Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types
3 sub-types
- Grade III lymphomatoid granulomatosis 4 trials
- Grade I lymphomatoid granulomatosis 0 trials
- Grade II lymphomatoid granulomatosis 0 trials
-
Hydroa vacciniforme-like lymphoma 3 trials
Most studied deeper sub-types
-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug targets virus to fight rare cancer
Disease control OngoingThis phase 2 trial tests a drug called VK-2019 in 13 patients with Epstein-Barr virus (EBV)-positive nasopharyngeal cancer that has returned or spread and has no standard treatment. VK-2019 works by blocking a key viral protein, EBNA1, which the virus needs to survive. The main g…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New cell therapy takes on virus-driven blood cancers in tiny early trial
Disease control By invitation onlyThis early study tests a new treatment called KSD-101 in 9 adults with blood cancers linked to the Epstein-Barr virus. The main goal is to find a safe dose and see if it shrinks tumors. Participants must have tried standard treatments without success.
Phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Donor immune cells show promise against Virus-Linked cancers
Disease control OngoingThis study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Supercharged t cells take on Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests whether specially trained immune cells (T cells) that are made resistant to a tumor's defense chemical can safely fight relapsed EBV-positive lymphoma. Eight patients will receive two injections of these modified cells, 14 days apart, at increasing do…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC